Saengsuree Jootar

2.2k total citations
75 papers, 1.5k citations indexed

About

Saengsuree Jootar is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Saengsuree Jootar has authored 75 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Hematology, 45 papers in Genetics and 14 papers in Rheumatology. Recurrent topics in Saengsuree Jootar's work include Chronic Myeloid Leukemia Treatments (39 papers), Chronic Lymphocytic Leukemia Research (33 papers) and Hematopoietic Stem Cell Transplantation (15 papers). Saengsuree Jootar is often cited by papers focused on Chronic Myeloid Leukemia Treatments (39 papers), Chronic Lymphocytic Leukemia Research (33 papers) and Hematopoietic Stem Cell Transplantation (15 papers). Saengsuree Jootar collaborates with scholars based in Thailand, South Korea and United States. Saengsuree Jootar's co-authors include Artit Ungkanont, Timothy P. Hughes, Suradej Hongeng, Ricardo Pasqüini, Jerzy Hołowiecki, Nelson Hamerschlak, Neil P. Shah, Samart Pakakasama, Hagop M. Kantarjian and Dong‐Wook Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Saengsuree Jootar

73 papers receiving 1.5k citations

Peers

Countries citing papers authored by Saengsuree Jootar

Since Specialization

Citations

This map shows the geographic impact of Saengsuree Jootar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saengsuree Jootar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saengsuree Jootar more than expected).

Fields of papers citing papers by Saengsuree Jootar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saengsuree Jootar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saengsuree Jootar. The network helps show where Saengsuree Jootar may publish in the future.

Co-authorship network of co-authors of Saengsuree Jootar

This figure shows the co-authorship network connecting the top 25 collaborators of Saengsuree Jootar. A scholar is included among the top collaborators of Saengsuree Jootar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saengsuree Jootar. Saengsuree Jootar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib 2018 ·Leukemia Research ·Sung‐Eun Lee, Soo-Young Choi, Soo-Hyun Kim, Saengsuree Jootar, Hyeoung‐Joon Kim, (unknown), Joon Seong Park, Sung‐Hyun Kim, (unknown), Sukjoong Oh, Dong‐Wook Kim	4
2	The use of hematocrit level for predicting the efficiency of peripheral blood CD34⁺ cell collection after G‐CSF Mobilization in Healthy Donors 2015 ·Journal of Clinical Apheresis ·(unknown), Pimjai Niparuck, (unknown), Teeraya Puavilai, Nongnuch Sirachainan, Samart Pakakasama, Suradej Hongeng, Saengsuree Jootar, Artit Ungkanont	15
3	Magnetic Nanoparticles PCR Enzyme‐Linked Gene Assay for Quantitative Detection of BCR/ABL Fusion Gene in Chronic Myelogenous Leukemia 2015 ·Journal of Clinical Laboratory Analysis ·(unknown), Duangporn Polpanich, (unknown), Raweewan Thiramanas, Suradej Hongeng, Budsaba Rerkamnuaychoke, Saengsuree Jootar, Pramuan Tangboriboonrat, Kulachart Jangpatarapongsa	9
4	Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand 2014 ·Clinical Therapeutics ·(unknown), (unknown), Saengsuree Jootar, Kanchana Chansung, Yot Teerawattananon	14
5	ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes 2013 ·Blood ·Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes, Richard E. Clark, Hirohisa Nakamae, Dong‐Wook Kim, Saengsuree Jootar, Gabriel Étienne, Ian W. Flinn, Jeffrey H. Lipton, Ricardo Pasqüini, Beatriz Moiraghi, (unknown), Xiaolin Fan, Hans D. Menssen, Hagop M. Kantarjian, Richard A. Larson	35
6	Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial 2012 ·Blood ·Sung‐Hyun Kim, Hari Menon, Saengsuree Jootar, Tapan Saikia, Jae‐Yong Kwak, Sang Kyun Sohn, Joon Seong Park, Hyeoung Joon Kim, (unknown), Suk Joong Oh, Hawk Kim, Dae Young Zang, Sa-Hee Park, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jae Soo Shin, (unknown), (unknown), (unknown), (unknown)	5
7	Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study 2012 ·Blood ·Soo-Young Choi, Sung‐Eun Lee, Soo-Hyun Kim, Eun‐Jung Jang, Jinhwa Lee, (unknown), Ju‐Hee Bang, (unknown), (unknown), (unknown), Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, Hyeoung‐Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung‐Hyun Kim, (unknown), Sukjoong Oh, Dong-Wook Kim	2
8	Expanding Nilotinib Access in Clinical Trials (ENACT) 2011 ·Cancer ·Franck E. Nicolini, Anna Turkina, Zhixiang Shen, Neil J. Gallagher, Saengsuree Jootar, Bayard L. Powell, Cármino Antônio De Souza, Ming Zheng, Tomasz Szczudlo, Philipp le Coutre	48
9	Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis 2011 ·Leukemia & lymphoma ·Franck E. Nicolini, Tamás Masszi, Zhixiang Shen, Neil J. Gallagher, Saengsuree Jootar, Bayard L. Powell, Pedro Enrique Dorlhiac‐Llacer, Ming Zheng, Tomasz Szczudlo, Anna Turkina	28
10	DNAdetection of chronic myelogenous leukemia by magnetic nanoparticles 2010 ·The Analyst ·Kulachart Jangpatarapongsa, Duangporn Polpanich, (unknown), (unknown), (unknown), Raweewan Thiramanas, Suradej Hongeng, Saengsuree Jootar, (unknown), Pramuan Tangboriboonrat	19
11	Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era 2010 ·Leukemia Research ·Dong‐Wook Kim, Shripad Banavali, Udomsak Bunworasate, (unknown), Peter Ganly, He Huang, (unknown), Saengsuree Jootar, Hyun‐Gyung Goh, Liang‐Piu Koh, Wei Li, Tomoki Naoe, (unknown), (unknown), (unknown), Lee‐Yung Shih, Jih‐Luh Tang, Arinobu Tojo, Jianmin Wang, Raymond Wong	33
12	Suppression of erythroid progenitor cells during malarial infection in Thai adults caused by serum inhibitor 2008 ·Clinical & Laboratory Haematology ·Saengsuree Jootar, (unknown), (unknown), (unknown), Wichai Prayoonwiwat, (unknown), Tanomsri Srichaikul	7
13	Chronic myeloid leukemia in Asia 2008 ·International Journal of Hematology ·Wing Y. Au, Priscilla B. Caguioa, Charles Chuah, (unknown), Saengsuree Jootar, Dong‐Wook Kim, (unknown), William M. O’Neil, (unknown), Jianxiang Wang	85
14	The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB109-DQB10309 2008 ·Nephrology Dialysis Transplantation ·Kearkiat Praditpornsilpa, Pawinee Kupatawintu, (unknown), (unknown), Saengsuree Jootar, (unknown), Cholatip Pongskul, Wisit Prasithsirikul, (unknown), (unknown), (unknown), Somchai Eiam‐Ong	24
15	Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients 2007 ·American Journal of Hematology ·Suradej Hongeng, Samart Pakakasama, Ampaiwan Chuansumrit, Nongnuch Sirachainan, Thanyachai Sura, Artit Ungkanont, Suporn Chuncharunee, Saengsuree Jootar, (unknown)	26
16	Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion 2006 ·Leukemia Research ·Saengsuree Jootar, (unknown), (unknown), (unknown), Sinee Disthabanchong, Samart Pakakasama, Artit Ungkanont, Suradej Hongeng	27
17	Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia 2006 ·Biology of Blood and Marrow Transplantation ·Suradej Hongeng, Samart Pakakasama, Ampaiwan Chuansumrit, Nongnuch Sirachainan, (unknown), Umaporn Udomsubpayakul, Artit Ungkanont, Saengsuree Jootar	46
18	Ongoing challenges of a global international patient assistance program 2006 ·Annals of Oncology ·(unknown), Saengsuree Jootar	14
19	Allogeneic Peripheral Blood Stem Cell Transplantation in Children With Homozygous ??-Thalassemia and Severe ??-Thalassemia/Hemoglobin E Disease 2004 ·Journal of Pediatric Hematology/Oncology ·Samart Pakakasama, Suradej Hongeng, (unknown), Ampaiwan Chuansumrit, (unknown), Saengsuree Jootar	9
20	Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases 1998 ·Leukemia Research ·Tanin Intragumtornchai, Wichai Prayoonwiwat, (unknown), (unknown), (unknown), Saengsuree Jootar, Kanchana Chansung, (unknown), (unknown), Yataro Yoshida	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact